ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) is -46.61% lower on its value in year-to-date trading and has touched a low of $1.79 and a high of $5.11 in the current 52-week trading range. The ZIOP stock was last observed hovering at around $2.65 in the last trading session, with the day’s loss setting it -0.13% off its average median price target of $6.00 for the next 12 months. It is also 66.4% off the consensus price target high of $7.50 offered by 8 analysts, but current levels are 16.0% higher than the price target low of $3.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $2.52, the stock is -10.50% and -4.65% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.64 million and changing -4.91% at the moment leaves the stock -11.17% off its SMA200. ZIOP registered -45.45% loss for a year compared to 6-month loss of -22.22%. The firm has a 50-day simple moving average (SMA 50) of $2.7987 and a 200-day simple moving average (SMA200) of $2.8414.
The stock witnessed a -11.58% gain in the last 1 month and extending the period to 3 months gives it a -3.82%, and is -13.10% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.86% over the week and 6.46% over the month.
Distance from 52-week low is 40.39% and -50.68% from its 52-week high.
ZIOPHARM Oncology Inc. (ZIOP) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for ZIOPHARM Oncology Inc. (ZIOP) is a “Overweight”. 8 analysts offering their recommendations for the stock have an average rating of 2.20, where 1 rate it as a Hold and 1 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
ZIOPHARM Oncology Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.1.The EPS is expected to shrink by -173.40% this year.
ZIOPHARM Oncology Inc. (ZIOP) Top Institutional Holders
205 institutions hold shares in ZIOPHARM Oncology Inc. (ZIOP), with 13.97M shares held by insiders accounting for 6.56% while institutional investors hold 59.06% of the company’s shares. The shares outstanding are 212.84M, and float is at 200.20M with Short Float at 16.69%. Institutions hold 55.19% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 15.28 million shares valued at $38.51 million. The investor’s holdings represent 7.13% of the ZIOP Shares outstanding. As of Sep 29, 2020, the second largest holder is MSD Partners, L.P. with 15.15 million shares valued at $38.18 million to account for 7.07% of the shares outstanding. The other top investors are Blackrock Inc. which holds 14.99 million shares representing 6.99% and valued at over $37.76 million, while Miller Value Partners, LLC holds 5.78% of the shares totaling 12.39 million with a market value of $31.21 million.
ZIOPHARM Oncology Inc. (ZIOP): Who are the competitors?
The company’s main competitors (and peers) include Cleveland BioLabs Inc. (CBLI) that is 460.98% higher over the past 12 months. Bristol-Myers Squibb Company (BMY) is -2.07% down on the 1-year trading charts. Short interest in the company’s stock has fallen -0.09% from the last report on Nov 12, 2020 to stand at a total of 33.44 million short shares sold with a short interest ratio of 19.43.